Recent studies indicate a significant increase in the number of poorly soluble drugs in development, with approximately 70% of novel pharmaceutical compounds exhibiting low aqueous solubility (Figure 1).
The in vivo bioavailability of oral formulations is predominantly influenced by solubility and dissolution kinetics within the gastrointestinal tract.
Consequently, enhancing in vitro dissolution and accelerating the rate at which these poorly soluble compounds dissolve — thereby improving their bioavailability — has emerged as a critical challenge in pharmaceutical formulation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.